FDA Grants Traditional Approval to Brexucabtagene Autoleucel for Relapsed or Refractory MCL
The FDA converted Tecartus from accelerated to traditional approval in relapsed or refractory mantle cell lymphoma, using confirmatory ZUMA-2 data.
TL;DR
- On April 2, 2026, the FDA granted traditional approval to brexucabtagene autoleucel (Tecartus) for adults with relapsed or refractory mantle cell lymphoma.
- In ZUMA-2 cohort 3, 86 treated patients who had not received a BTK inhibitor had an objective response rate of 91% and a complete remission rate of 79%.
- Pooled safety across 168 patients showed cytokine release syndrome in 93% and neurologic events in 80%. The study was single-arm, so it does not compare Tecartus with another treatment.
The FDA granted traditional approval to the CD19-directed CAR-T therapy brexucabtagene autoleucel (Tecartus) for adults with relapsed or refractory mantle cell lymphoma. The ASCO Post and OncLive both reported that the action converts the earlier accelerated approval and adds confirmatory data from cohort 3 of the single-arm ZUMA-2 study, in patients whose disease relapsed or was refractory after one or more lines of therapy and who had not received a BTK inhibitor. [1, 2] [1] [2]
ZUMA-2 is an open-label multicenter study. Cohorts 1 and 2 treated 82 patients who had received up to five prior lines, including chemotherapy, an anti-CD20 antibody, and a BTK inhibitor. Cohort 3 treated 86 patients who were BTK-inhibitor naive. The primary endpoint was objective response rate by independent review under the Lugano 2014 criteria. [1, 2] [1] [2]
In cohort 3, the objective response rate was 91% and the complete remission rate was 79%, with median duration of response not reached at a median follow-up of 23.0 months. In cohort 1, the objective response rate was 87% and the complete remission rate was 62%, with median duration of response not reached at 8.6 months of follow-up. Both reports describe the responses as high and the safety profile as consistent with earlier experience. [1, 2] [1] [2]
In the pooled mantle-cell population of 168 patients, cytokine release syndrome occurred in 93%, including grade 3 or higher in 12%, and neurologic events occurred in 80%, including grade 3 or higher in 33%. Infections of any grade occurred in 63%, including grade 3 or higher in 33%. In cohort 3, serious adverse reactions occurred in 65% of patients. Because the trial has no control arm, the reports do not establish how these results compare with another regimen. [1, 2] [1] [2]
Why it matters
Traditional approval means the confirmatory study fulfilled the postmarketing requirement that had kept this Tecartus indication on the accelerated pathway. For the CAR-T field, the cohort 3 data extend the labeled evidence to patients who have not yet received a BTK inhibitor, while the single-arm design still leaves comparative effectiveness open.
Editor's note
Manual catch-up of the April 2, 2026 approval, which was not in an earlier edition. Response rates are those reported by both outlets. Conflicting trial-identifier details between outlets were left out. No treatment recommendation.